MZTI arrives at this week's note bruised from a revenue miss, a fresh analyst target cut, and options positioning that has turned sharply defensive — while a completed acquisition adds a new strategic layer that the market is still processing.
The clearest signal this week is in the options market. Put demand has surged well above its recent norm, with the put/call ratio jumping to 2.95 — nearly 2.5 standard deviations above its 20-day average of 2.06. That is close to the most extreme defensive reading of the past year, which peaked at 4.03. The shift was abrupt: the PCR sat around 1.86–1.97 through most of April before leaping to 3.28 on May 4 in the immediate aftermath of the Q3 earnings release, then easing slightly to 2.95 by May 5. Investors are reaching for downside protection at a rate well above what has been normal.
The catalyst is clear. Marzetti reported Q3 results on May 4 with revenue flat year-on-year at $453.4 million — a miss against Wall Street's expectations. The stock dropped 4.6% the following day and is now down 6.5% on the week and 16.2% over the past month to close at $118.71. Soybean oil inflation and volume weakness were cited as headwinds, and the company's guidance comments around Bachan's — the Japanese BBQ sauce brand it just finished acquiring — pointed to a Q4 net sales run rate moderately above $87 million, providing some offset but not enough to shift sentiment on the day. A next earnings event is already flagged for May 7, suggesting another update is imminent.
Short interest tells a more notable story than it did a month ago. Shorts have now built to 4.6% of the free float — up 71% over the past 30 days — with shares short climbing from around 740,000 at end-March to over 1.26 million by May 5. The weekly change is a modest 2.4%, but the monthly trajectory is hard to ignore: the acceleration began in mid-April and has not reversed. That said, the borrow market remains almost entirely unconstrained. Cost to borrow is just 0.40% — cheap by any measure — and availability in the lending pool is extremely loose. There is no squeeze dynamic here; the shorts are comfortable and not under pressure.
The analyst community is broadly neutral but nudging targets lower. Stephens & Co. cut its price target a second time in roughly two weeks — from $160 to $140 today — while keeping the Equal-Weight rating unchanged. DA Davidson trimmed from $184 to $168 in March, also holding Neutral. The consensus mean target is $159.40, which implies roughly 34% upside from current levels, though that gap largely reflects how far the stock has already fallen rather than any bullish conviction. Neither firm has upgraded. The direction of travel on targets has been consistently downward since late 2025, and there is no recent rating change suggesting the Street is ready to step in front of the tape.
On valuation, the de-rating is visible. The P/E has compressed by about 3 points over the past 30 days to 17.1x, and EV/EBITDA has ticked up slightly to 10.1x as the enterprise value outpaces any earnings improvement. One factor score stands out: dividend quality ranks in the 93rd percentile, suggesting the income profile remains intact even as growth concerns mount. The short score at 44.6 is mid-range and has been relatively stable — consistent with a building but not yet crowded short position.
What to watch next: the May 7 earnings update will be the immediate focus, with particular attention on whether Bachan's integration commentary sharpens the outlook for the back half of the fiscal year, and whether soybean oil cost pressures show any sign of abating.
See the live data behind this article on ORTEX.
Open MZTI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
